Plain-English translation of NCT06730542 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This study is testing a new treatment approach for a serious type of lymphoma—a blood cancer—that has spread to the brain and nervous system. The treatment combines three medications: (a newer targeted drug), plus two chemotherapy drugs, and high-dose . Researchers want to understand how well this medication combination works and what side effects patients may experience.
Lymphoma that spreads to the brain is difficult to treat and has limited effective options. This trial exists to see whether adding to the standard chemotherapy approach can improve outcomes for patients facing this serious diagnosis.
You likely qualify if…
You likely don't qualify if…
You would take the three-medication combination as part of a treatment plan lasting up to 2 years. This involves receiving the chemotherapy drugs intravenously (through an IV) and taking by mouth, along with high-dose doses. You would have regular clinic visits for monitoring, blood tests, and imaging scans to track how the treatment is working and to watch for side effects. The study involves close follow-up with your medical team throughout the treatment period.
AI-generated summary from trial data · Jun 24, 2026 · Not medical advice
United States
Phase
Safety & dosing
Sponsor
Juan P. Alderuccio, MD
Collaborators
BeiGene
Enrollment target
~20 participants
Started
April 2025
Primary completion
April 2030
Age range
18 Years and older
Last updated on clinicaltrials.gov in May 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Juan P Alderuccio, MD
University of Miami
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.